ARWR vs WVE Stock Comparison
Compare ARWR and WVE across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between ARWR and WVE?
WVE leads the current stock comparison as Wave Life Sciences Ltd., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Arrowhead Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
WVE leads
WVE leads by 3 AIQ points, primarily on Quality, having only recently taken the lead back from ARWR.
Fragile: 1 of 6 evidence groups support WVE, and the lead recently changed hands.
Arrowhead Pharmaceuticals, Inc.
Wave Life Sciences Ltd.
The Algovestiq AIQ Score currently favors WVE over ARWR, 40 versus 37 as of Sep 11, 2026. WVE's advantage is driven primarily by stronger quality, while ARWR holds the stronger risk resilience profile. WVE also shows the weaker technical structure relative to its 50-day moving average. 1 of 6 covered evidence groups favor WVE today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. WVE lead: Reversed — ARWR led by 2 AIQ points 30 sessions ago; WVE now leads by 3.
Compare Arrowhead Pharmaceuticals, Inc. and Wave Life Sciences Ltd. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare ARWR and WVE against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality32 vs 59WVE +27
- Risk Resilience57 vs 40ARWR +17
- Momentum35 vs 25ARWR +10
- Value34 vs 34Even
1 of 6 evidence groups favor WVE. WVE’s edge is concentrated in quality; ARWR keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +3
No new signals fired.
No factor moved materially.
No new signals fired.
WVE's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — ARWR and WVE both carry a full feed there.
The central trade-off
WVE (Wave Life Sciences Ltd.): the stronger current systematic profile, led by quality.
ARWR (Arrowhead Pharmaceuticals, Inc.): the counter-case, on risk resilience, momentum, fundamentals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
WVEWVE on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ARWRARWR on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
ARWRARWR on the Momentum factor, by 10 points.
Lower downside
ARWRARWR on Risk Resilience, by 17 points.
Analyst upside
WVEWVE on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | ARWR | WVE | Note |
|---|---|---|---|
| Implied upside to target | +24.4% | +212.2% | WVE has more room |
| Target dispersion | +77.6% | +41.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 7 | 7 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
1 of 6 covered evidence groups favor WVE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 37 vs 40 |
| Fundamentals | ARWRon balance | revenue growth 2.1% vs -94.1%; EPS growth -46.2% vs -161.5%; TTM ROE -60.5% vs -50.1%; gross margin 100% vs 96.5%; operating margin -33.8% vs -3.3% — ARWR takes 3 of 5 decided legs, not all of them |
| Valuation | Even | Value 34 vs 34 |
| Technicals | ARWR | Price vs 50-day -1.6% vs -17.6%; vs 200-day 15.3% vs -49.5% |
| Risk Resilience | ARWR | Risk Resilience 57 vs 40 |
| Analyst expectations | WVE | Target upside 24.4% vs 212.2% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ARWR and WVE and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
- Only 1 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on WVE.
How the comparison changed
119 daily snapshots · May 4 – Sep 10WVE lead: Reversed — ARWR led by 2 AIQ points 30 sessions ago; WVE now leads by 3.
- Today
- WVE +3
- 37 vs 40
- 7 sessions ago
- WVE +1
- 42 vs 43
- 30 sessions ago
- ARWR +2
- 45 vs 43
- 90 sessions ago
- ARWR +1
- 48 vs 47
The lead changed hands 11 times in this window, most recently on Sep 9 when WVE moved ahead of ARWR.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 1 bearish / 1 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (17.27%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.07%)
- MACD Bearish Crossover — bearish, momentum, short horizon
0 bullish / 4 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (66.61%)
- 52-Week Low Proximity — bearish, risk, long horizon (0.0%)
- Downtrend Structure Active — bearish, trend, long horizon
ARWR is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +0.11%, AIQ +1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.71%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1ARWR closes the Quality gap — currently 27 points behind, the largest single contributor to WVE's edge.
- 2ARWR's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it.
- 3WVE starts generating bearish momentum or trend signals.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ARWR leads on balance| Metric | ARWR | WVE |
|---|---|---|
| Revenue growth (YoY) | 2.1% | -94.1% |
| EPS growth (YoY) | -46.2% | -161.5% |
| Gross margin | 100% | 96.5% |
| Operating margin | -33.8% | -3.3% |
| Return on equity (TTM) | -60.5% | -50.1% |
| Debt to equity | 1.86 | 0.1 |
Performance
ARWR leads 6 of 6 windows| Metric | ARWR | WVE |
|---|---|---|
| 1 week (5 sessions) | -3.1% | -4.3% |
| 1 month (20 sessions) | -5.1% | -10.9% |
| 3 months (63 sessions) | 17% | -17.5% |
| 6 months (126 sessions) | 42.4% | -66.8% |
| Year to date | 24.7% | -71.4% |
| 1 year (252 sessions) | 204.6% | -38.4% |
Technicals
ARWR has the stronger structure| Metric | ARWR | WVE |
|---|---|---|
| RSI (14) | 36.9 | 30.4 |
| ADX (14) | 14.9 | 35.6 |
| Price vs 50-day | -1.6% | -17.6% |
| Price vs 200-day | 15.3% | -49.5% |
| Volatility (1M, annualized) | 31.2% | 45.1% |
Risk
ARWR is the more resilient| Metric | ARWR | WVE |
|---|---|---|
| Beta | 1.55 | 1.35 |
| Sharpe ratio | 2.03 | 0.27 |
| Sortino ratio | 4.06 | 0.57 |
| Max drawdown | -24.6% | -78.1% |
| Current drawdown | -7.6% | -78.1% |
| Annualized volatility | 61% | 168.1% |
| Value at risk (95%) | -5% | -5.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ARWR or WVE?
On the Algovestiq AIQ Score, WVE is the stronger of the two as of Sep 11, 2026, scoring 40 against ARWR's 37. The edge comes from quality. ARWR is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ARWR or WVE the better buy right now?
WVE carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 1 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.
Why does the AIQ Score favor WVE over ARWR?
The composite weights Quality, Value, Momentum and Risk Resilience. WVE leads Quality by 27 points; ARWR leads Risk Resilience by 17 points; ARWR leads Momentum by 10 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ARWR or WVE?
Analyst price targets imply +24.4% upside for ARWR and +212.2% for WVE, so the Street currently favors WVE. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ARWR or WVE?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ARWR or WVE?
ARWR on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ARWR or WVE?
ARWR on the Momentum factor, by 10 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ARWR or WVE?
ARWR is the more resilient of the two, so the other name carries the higher downside risk. ARWR on Risk Resilience, by 17 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ARWR more profitable than WVE?
The profitability evidence is mixed: gross margin 100% vs 96.5%; operating margin -33.8% vs -3.3%; ttm roe -60.5% vs -50.1%. ARWR leads on one measure and WVE on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is WVE's lead over ARWR getting stronger or weaker?
WVE lead: Reversed — ARWR led by 2 AIQ points 30 sessions ago; WVE now leads by 3. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 11 times in that window, most recently on 2026-09-09, when WVE moved ahead of ARWR.
What would change the ARWR vs WVE verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ARWR closes the Quality gap — currently 27 points behind, the largest single contributor to WVE's edge; ARWR's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it; WVE starts generating bearish momentum or trend signals; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about ARWR and WVE?
ARWR: 1 bullish / 1 bearish / 1 neutral, conflicted. WVE: 0 bullish / 4 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ARWR is Golden Cross Active (bullish, long horizon). On WVE it is Death Cross Active (bearish, long horizon).
Compare ARWR and WVE with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.